Halberd Corp HALB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HALB is a good fit for your portfolio.
News
-
Halberd's Patented Drug, LDN+, the Subject of a Limited Clinical Trial Under an Innovative Four-Company Cooperative Research and Development (CRADA) Contract
-
Halberd and Mississippi State University to Commence Stage II Advanced TBI Nasal Spray Testing
-
Halberd's Top Executives Join Forces with Athena GTX CEO Mark Darrah Unveiling 2024 Powerful Partnership Outlook on "The Street Reports Podcast"
Trading Information
- Previous Close Price
- $0.01
- Day Range
- $0.01–0.01
- 52-Week Range
- $0.00–0.01
- Bid/Ask
- $0.01 / $0.01
- Market Cap
- $218,756.91
- Volume/Avg
- 1.6 Mil / 1.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1,820.00
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 3
Valuation
|
Metric
|
HALB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 1,820.00 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
HALB
|
|---|---|
Quick Ratio | 0.01 |
Current Ratio | 0.01 |
Interest Coverage | −65.02 |
Quick Ratio
HALB
Profitability
|
Metric
|
HALB
|
|---|---|
Return on Assets (Normalized) | −3,091.66% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
HALB
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ctzsmytsk | Cfd | $559.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Lpgpjbcv | Dcfgsf | $102.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Smyfnlcbm | Cqpqhn | $98.6 Bil | |
MRNA
| Moderna Inc | Ghvyzndbv | Vyfl | $41.0 Bil | |
ARGX
| argenx SE ADR | Tcjgwgbb | Jhd | $22.6 Bil | |
BNTX
| BioNTech SE ADR | Cbzjkxfnm | Fbzf | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Pnmxthtqh | Dbspqr | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Twtdzxyhf | Ckpxvrq | $17.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xfsvqwbl | Crvtg | $12.6 Bil | |
INCY
| Incyte Corp | Tnfrbskhc | Rvdxhvf | $12.0 Bil |